Craif
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Series B | ||
N/A | $11.3m | Early VC | |
N/A | Series B | ||
N/A | JPY1.5b | Late VC | |
* | N/A | Late VC | |
Total Funding | €21.4m |
Recent News about Craif
EditCraif Inc. is a molecular diagnostics company focused on developing innovative solutions for early cancer detection using miRNA-based technology. Founded in May 2018 by Ryuichi Onose and Yasui Takao, the company operates in the life sciences sector, serving healthcare providers, medical researchers, and diagnostic laboratories. Craif's core product is a miRNA-based platform designed to identify cancer at its earliest stages, thereby improving patient outcomes and reducing healthcare costs. The company generates revenue through the sale of diagnostic tests and partnerships with healthcare institutions and research organizations. Craif was selected for the 2024 Medtech Innovator Accelerator Cohort, highlighting its potential and innovation in the medical technology field.
Keywords: miRNA, early cancer detection, molecular diagnostics, healthcare, life sciences, innovation, Medtech, diagnostic tests, biotechnology, medical research.